CCA
SMMT icon

Checchi Capital Advisers’s Summit Therapeutics SMMT Stock Holding History

Checchi Capital Advisers’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-20,000
Closed -$59K – 478
2020
Q2 		$59K Buy
+20,000
New +$69K 0.01% 450

Other funds holding SMMT

PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BP
BBR Partners New York $2.13B AUM 21.87% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.05B AUM 22.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $239B AUM 42.32% 1-Year Est. Return

Checchi Capital Advisers's SMMT Position: Q3 2020 in Review

Checchi Capital Advisers sold out of Summit Therapeutics (SMMT) in Q3 2020, closing a stake of 20,000 shares — an estimated $59K sold.

Checchi Capital Advisers first reported a position in SMMT in Q2 2020 and held it in 1 quarter. The position peaked at $59K in Q2 2020. 19 funds tracked by Wall St. Rank hold SMMT as of Q3 2020.

  • Checchi Capital Advisers reported no remaining Summit Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Checchi Capital Advisers sold 20,000 Summit Therapeutics shares in Q3 2020, an estimated $59K.
  • Checchi Capital Advisers first reported a position in Summit Therapeutics in Q2 2020 and held it in 1 quarter.
  • Checchi Capital Advisers's Summit Therapeutics position peaked at $59K in Q2 2020.
  • 19 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2020.

Based on Checchi Capital Advisers's 13F filing for Q3 2020, filed 10 Nov 2020.